The medical application of its product Botox for chronic migraines provides a diversified and resilient revenue stream, indicating a strong market position and defensive sales characteristics beyond cosmetic use.

Faces increased competition sooner than expected for its branded biologic drugs like Humira due to the FDA speeding up the approval process for biosimilars, which could pressure market share and pricing power.

Speaker sees significant, underappreciated value in its drug pipeline, calling its drug Skyrizi 'probably the most important medicine in the world right now.'

The speaker mentioned this as a long position that he 'bought back' into after selling other positions.

The speaker has 'never liked' the company, stating it operates in 'really slow growth markets' and is, at best, fairly valued. It is suggested as a short against more interesting companies.